Developing new treatments for rare and orphan neurological conditions.
Location: United States, Illinois, Chicago
Total raised: $285M
Investors 3
| Date | Name | Website |
| 18.07.2021 | Valor Equi... | valorep.co... |
| - | Horizon Te... | horizontec... |
| 16.11.2022 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.11.2022 | Series D | $250M | - |
| 23.03.2021 | Series C | $35M | - |
Mentions in press and media 12
| Date | Title | Description |
| 03.01.2023 | This biotech founder has a new plan to treat Tourette Syndrome, which affects 200,000 Americans each year | Jeff Aronin, CEO of Paragon Biosciences and founder of Emalex Biosciences. Paragon Biosciences Emalex Bioscience is developing a new treatment for Tourette Syndrome. The disease affects around 1 in 160 children and has no cure. Emalex found... |
| 04.11.2022 | Emalex Biosciences Raises $250M in Series D Financing Round | Emalex Biosciences, a Chicago, IL-based biotechnology company, raised $250M in Series D funding. The round was led by Bain Capital Life Sciences with participation from Paragon Biosciences, Valor Equity Partners, and Fidelity Management &am... |
| 03.11.2022 | Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test of Tourette Drug | Tourette syndrome causes involuntary muscle and vocal tics that can be treated with several drugs, but most of them work the same way. Emalex Biosciences’ experimental drug hits a different central nervous system target and the biotech has ... |
| 03.11.2022 | Emalex Raises $250M For Tourette Syndrome Treatment | 4 Shares Email Facebook Twitter LinkedIn Not all late-stage companies are feeling the funding drought. Biotech startup Emalex Biosciences announced on Thursday its $250 million Series D raise, led by Bain Capital. Also participating were Pa... |
| 03.11.2022 | Emalex Biosciences Announces $250M Series D | CHICAGO, IL, Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round. >> Click here for more funding data on Emalex Biosciences >> To export Emalex Biosciences funding da... |
| 23.03.2021 | Emalex Biosciences Raises $35M in Series C Funding | Emalex Biosciences, Inc., a Chicago, IL-based biopharmaceutical company founded to develop treatments for central nervous system movement disorders and fluency disorders, raised $35m in Series C funding. The round was led by Paragon Bioscie... |
| 23.03.2021 | Jeff Aronin's Emalex raises $35M Series C; British protein degradation biotech emerges from stealth | Jeff Aronin has a new raise in place for one of his portfolio companies. Emalex Biosciences is banking a $35 million C round for its work on a drug for Tourette syndrome and stuttering. The biotech will use the money to advance ... |
| 23.03.2021 | Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials | |
| 23.03.2021 | Emalex Biosciences Scoops Up $35M Series C | CHICAGO, IL, Emalex Biosciences today announced $35 million in Series C Preferred Stock funding. >> Click here for more funding data on Emalex Biosciences >> To export Emalex Biosciences funding data to PDF and Excel, click ... |
| - | Investors have poured $548 million into neuroscience biotechs this year. Meet the 10 startups that have raised the most cash. | Peter Anastasiou, the CEO of Capsida Biotherapeutics. Capsida Biotherapeutics This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Neuroscience companies have raised more money from VCs in rec... |
Show more